Hepatology
From the Journals
Bezafibrate eased pruritus in patients with fibrosing cholangiopathies
In all, 45% of bezafibrate recipients had at least a 50% decrease in pruritus on a 10-point visual analog scale, compared with 11% of the placebo...
From the Journals
AGA Clinical Practice Update: How diet and exercise can help manage NAFLD
NAFLD affects approximately 25% of individuals worldwide, but medication, bariatric endoscopy, and surgery are reserved for only a small subset....
Case Reports
17-year-old girl • abdominal pain • lower-leg itching • dark urine and yellow eyes • Dx?
► Abdominal pain
► Lower-leg itching
► Dark urine & yellow eyes
News
Endoscopic intragastric balloon improved NASH parameters
At 6 months, nonalcoholic fatty liver disease activity scores had improved in 18 of 20 biopsied patients (90%), with a median decrease of 3 points...
Conference Coverage
HCC rates slow in cities, continue to climb in rural areas
Disparities in hepatocellular carcinoma incidence rates between urban and rural areas vary by race/ethnicity.
Conference Coverage
Harnessing the HIV care continuum model to improve HCV treatment success
Substance use, trauma histories, and mental health problems can negatively affect HCV care engagement.
Conference Coverage
Liver-related deaths decline after Medicaid expansion under ACA
Investment in Medicaid expansions paid off in fewer liver-related deaths and a decrease in racial/ethnic disparities.
Conference Coverage
Liver injury linked to COVID-19–related coagulopathy
Cells that line the liver’s blood vessels produce high levels of factor VIII, a coagulation factor, when they are exposed to interleukin-6, an...
Conference Coverage
Liquid biopsy captures key NASH pathology hallmarks
Scanning for key proteins in serum identified fibrosis, inflammation, hepatocyte ballooning, and steatosis with high accuracy.
From the Journals
Semaglutide shows promise in NASH phase 2 study
The drug “bodes well for further study” in a condition with no FDA approved treatments.
From the Journals
Lipid profiles distinguish obese and nonobese NAFLD patients
Distinct lipid combinations showed noninvasive predictive potential for both obese and nonobese nonalcoholic fatty liver disease patients.